Huang D, Wong V, Rinella M, Boursier J, Lazarus J, Yki-Jarvinen H
Nat Rev Dis Primers. 2025; 11(1):14.
PMID: 40050362
DOI: 10.1038/s41572-025-00599-1.
Lian Y, Wang Y, Yang Y, Chen J
BMC Gastroenterol. 2025; 25(1):137.
PMID: 40045243
PMC: 11884151.
DOI: 10.1186/s12876-025-03706-4.
Jarmakiewicz-Czaja S, Sokal-Dembowska A, Filip R
Medicina (Kaunas). 2025; 61(2).
PMID: 40005309
PMC: 11857189.
DOI: 10.3390/medicina61020192.
Byrne C, Armandi A, Pellegrinelli V, Vidal-Puig A, Bugianesi E
Nat Rev Gastroenterol Hepatol. 2025; .
PMID: 39962331
DOI: 10.1038/s41575-025-01045-z.
Wang Y, Zhang Y, Wang Y
Int J Mol Sci. 2025; 26(3).
PMID: 39940822
PMC: 11817368.
DOI: 10.3390/ijms26031051.
The protective effects and mechanism of myricetin in liver diseases (Review).
Chen M, Zhang S, Huang X, Zhang D, Zhu D, Ouyang C
Mol Med Rep. 2025; 31(4).
PMID: 39917997
PMC: 11811602.
DOI: 10.3892/mmr.2025.13452.
Impaired RelA signaling and lipid metabolism dysregulation in hepatocytes: driving forces in the progression of metabolic dysfunction-associated steatotic liver disease.
He Y, Jiang J, Ou L, Chen Y, Abudukeremu A, Chen G
Cell Death Discov. 2025; 11(1):49.
PMID: 39910053
PMC: 11799324.
DOI: 10.1038/s41420-025-02312-3.
Potential therapeutic strategies for MASH: from preclinical to clinical development.
Xie Z, Li Y, Cheng L, Huang Y, Rao W, Shi H
Life Metab. 2025; 3(5):loae029.
PMID: 39872142
PMC: 11749562.
DOI: 10.1093/lifemeta/loae029.
Short-Term Evolution of MASLD Following Roux-en-Y Gastric Bypass: A Focus on Fibrotic MASH.
Bornia Matavelli C, Echeverria L, Pereira L, Chrispim I, Mounzer D, Chaim F
Obes Surg. 2025; 35(3):926-933.
PMID: 39870941
DOI: 10.1007/s11695-025-07688-w.
Ellagic Acid Modulates Necroptosis, Autophagy, Inflammations, and Stress to Ameliorate Nonalcoholic Liver Fatty Disease in a Rat Model.
Li Z, Li J, He S, Chen J, Deng C, Duan J
Food Sci Nutr. 2025; 13(1):e4694.
PMID: 39830906
PMC: 11742184.
DOI: 10.1002/fsn3.4694.
The association between the dietary index for gut microbiota and metabolic dysfunction-associated fatty liver disease: a cross-sectional study.
Zheng Y, Hou J, Guo S, Song J
Diabetol Metab Syndr. 2025; 17(1):17.
PMID: 39825360
PMC: 11740478.
DOI: 10.1186/s13098-025-01589-9.
Extracellular vesicle-mediated approaches for the diagnosis and therapy of MASLD: current advances and future prospective.
Gurjar S, Bhat A R, Upadhya R, Shenoy R
Lipids Health Dis. 2025; 24(1):5.
PMID: 39773634
PMC: 11705780.
DOI: 10.1186/s12944-024-02396-3.
Correlation Among Psoriasis, Iridocyclitis, and Non-alcoholic Fatty Liver Disease: Insights from Mendelian Randomization and Mediation Analysis.
Xu S, Liu L, Li C, Ren Y, Zhang M, Xiang L
Int J Med Sci. 2025; 22(1):121-131.
PMID: 39744174
PMC: 11659831.
DOI: 10.7150/ijms.102369.
The steatotic liver disease burden paradox: unravelling the key role of alcohol.
Torp N, Israelsen M, Krag A
Nat Rev Gastroenterol Hepatol. 2024; .
PMID: 39639157
DOI: 10.1038/s41575-024-01022-y.
Impact of Sodium-Glucose Co-Transporter Type-2 Inhibitors on Alanine Aminotransferase Levels in Type-2 Diabetes Patients Having Features of Nonalcoholic Fatty Liver Disease: A Retrospective Cohort Study in Pakistan.
Ansari A, Rizwan A, Khan U, Azam S
Pak J Med Sci. 2024; 40(11):2681-2688.
PMID: 39634912
PMC: 11613383.
DOI: 10.12669/pjms.40.11.8900.
Metabolic Dysfunction-Associated Steatotic Liver Disease in Type 2 Diabetes Mellitus: A Review and Position Statement of the Fatty Liver Research Group of the Korean Diabetes Association.
Bae J, Han E, Lee H, Park C, Chung C, Lee D
Diabetes Metab J. 2024; 48(6):1015-1028.
PMID: 39610131
PMC: 11621661.
DOI: 10.4093/dmj.2024.0541.
Recent Advances in miRNA-Based Therapy for MASLD/MASH and MASH-Associated HCC.
Carpi S, Daniele S, de Almeida J, Gabbia D
Int J Mol Sci. 2024; 25(22).
PMID: 39596297
PMC: 11595301.
DOI: 10.3390/ijms252212229.
Non-Targeted Metabolomics Reveal Apomorphine's Therapeutic Effects and Lysophospholipid Alterations in Steatohepatitis.
Ogiso H, Miura K, Nagai R, Osaka H, Aizawa K
Antioxidants (Basel). 2024; 13(11).
PMID: 39594434
PMC: 11591194.
DOI: 10.3390/antiox13111293.
Exploratory Role of Flavonoids on Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in a South Italian Cohort.
Bonfiglio C, Tatoli R, Donghia R, Guido D, Giannelli G
Antioxidants (Basel). 2024; 13(11).
PMID: 39594428
PMC: 11591465.
DOI: 10.3390/antiox13111286.
Metabolic dysfunction-associated steatotic liver disease: The question of long-term high-normal alanine aminotransferase as a screening test.
Moyana T
World J Gastroenterol. 2024; 30(42):4576-4582.
PMID: 39563746
PMC: 11572615.
DOI: 10.3748/wjg.v30.i42.4576.